Evidence map›Paper›PMID 35153049›Full record

ReviewClinics in laboratory medicine2022

Suboptimal Humoral Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Viral Variant Generation.

Shiv Pillai

Open access · greenAbstract readReview
In one paragraph

Review in Clinics in laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shiv PillaiRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA 02139, USA. Electronic address: pillai@helix.mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · US

Funding

The importance of the IgG4 glycome in IgG4-related disease(s)U19AI110495 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SHIV Subramaniam PILLAI · 2014 to 2026
$7.9M
NIAID NIH HHS U19 AI110495
6 · The paper itself

Abstract

This review describes the underlying basis for the sup-optimal humoral immune response in coronavirus disease (COVID)-19 including the absence of evidence for affinity maturation in the vast majority of patients and the absence of germinal centers even in severe disease. Suboptimal humoral and cellular immunity may provide the optimal conditions for the generation and selection of viral variants.

Indexed as

COVID-19Immunity, HumoralAntibodies, ViralHumansImmunity, CellularSARS-CoV-2Antibodies, ViralCOVID-19Germinal centersHumoral immunityImmune pressureSARS-CoV-2T follicular helper cellsVariant generation

Identifiers

PMID35153049
PMCPMC8563339
OpenAlexW3211225765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.